Social Media Ideas for Cinclus Pharma

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>

<![CDATA[Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Se...

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Wed, 07/29/2026 - 18:25 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals ]]>

<![CDATA[Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifyin...

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in pr...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

<![CDATA[Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement ]]>

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding

Slate, Fulcrum to combine in reverse merger

Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.

Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine

Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering...

GSK shelves cough drug acquired in $2B deal

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

<![CDATA[Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financi...

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Supernus, Individor merge to beef up brain drug portfolio

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Pa...

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials

Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical d...

<![CDATA[M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Ent...

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>

<![CDATA[Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutic...

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals...

Dianthus gains new Buy from Citi on multi-blockbuster potential for lead drug